Panelists discuss the role of communication, follow-up, and safety monitoring in optimizing long-term biologic therapy outcomes.
Dermatology Times, Advancing Biologic Treatment Strategies in Hidradenitis Suppurativa, March 2026 (Vol. 47. Supp. 03)
Panelists discuss the role of communication, follow-up, and safety monitoring in optimizing long-term biologic therapy outcomes.
Experts discuss how clinicians identify the right moment to transition from conventional therapy to biologic treatment in patients with hidradenitis suppurativa (HS).
Advertisement
Advertisement
Trending on Dermatology Times
1
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5